<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445898</url>
  </required_header>
  <id_info>
    <org_study_id>HK_VL_01_2015</org_study_id>
    <secondary_id>2015-000102-19</secondary_id>
    <nct_id>NCT02445898</nct_id>
  </id_info>
  <brief_title>Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients</brief_title>
  <official_title>Effect of Preoperative Intravenous High Dose Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Patients Scheduled for Total Hip-arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the pathophysiological effects of a single dose Methylprednisolone
      administered prior to total hip-arthroplasty (THA) surgery. The investigators examine the
      effect on orthostatic intolerance, orthostatic hypotension and heart rate variability (HRV)
      to evaluate the efficacy of Methylprednisolone regarding blood pressure regulation and
      autonomic responses after THA.

      Half of participants will receive intravenous Solu-Medrol 125 mg, while the other half will
      receive placebo.

      The investigators hypothesize that the group receiving Methylprednisolone will be less
      orthostatic intolerant, experience less orthostatic hypotension and have an improved
      autonomic response compared to the placebo-group, early after THA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The anti-inflammatory effects of glucocorticoids are well known. The beneficial effects in
      postoperative pain, postoperative nausea and vomiting are well-documented.

      Hip-arthroplasty surgery and the inflammatory stress response in general affect the potential
      of recovery. Early postoperative orthostatic intolerance is common in patients undergoing THA
      with an incidence of 40%. The mechanism is thought related to an impaired autonomic
      regulation caused by surgery-induced inflammation. The effect of glucocorticoids on
      orthostatic intolerance, orthostatic hypotension and HRV after hip-arthroplasty surgery is
      unknown and calls for further investigation.

      The study is to be considered as exploratory. The primary analysis of the primary outcome
      measure is a comparison of the incidence of orthostatic intolerance from baseline to 6 hours
      postoperatively between the two groups.

      For calculation of sample size the difference in incidence between groups (40% versus 10%)
      from baseline (before surgery) to 6 hours after THA-surgery, a risk of type I errors 5% and a
      risk of type II errors 20% (80% power) were used.

      The primary analysis is carried out on all included patients (intention-to-treat) with
      baseline values as covariate. Secondary exploratory per-protocol analysis might be performed.
      Missing outcomes will be analysed using multiple imputation due to expected strong time
      trends.

      The secondary outcomes measures; Non-invasive blood pressure, systemic vascular resistance,
      cardiac output, HRV, plasma-hemoglobin, C-reactive protein.

      For further details please also view the European Clinical Trials Database (EudraCT)
      registration:

      EudraCT nr.: 2015-000102-19
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in incidence of orthostatic intolerance from baseline to 6 hours after surgery</measure>
    <time_frame>6 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in incidence of orthostatic intolerance from baseline to 24 hours after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-invasive blood pressure from baseline to 24 hours after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate variability from baseline to 24 hours after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stroke volume and cardiac output from baseline to 24 hours after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systemic vascular resistance from baseline to 24 hours after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain intensity from baseline to 24 hours after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of plasma-hemoglobin from baseline to 48 hours after surgery</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of C-reactive protein from baseline to 48 hours after surgery</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Osteoarthrosis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative single high dose of Solu-Medrol 125 mg iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic Sodium Chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative single dose of isotonic Sodium Chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic Sodium Chloride</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Isotonic Sodium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthrosis

          -  Undergoing total unilateral hip-arthroplasty surgery

          -  Speak and understand Danish

          -  Have given informed content

        Exclusion Criteria:

          -  Revision or bilateral hip-arthroplasty surgery

          -  General anaesthesia

          -  Allergy or intolerance towards Methylprednisolone

          -  Local or systemic infection

          -  Permanent systemic treatment with steroids within 30 days peroperatively

          -  Insulin-dependent diabetes

          -  Atrial fibrillation

          -  Neurological disease incl. Parkinsons

          -  Daily use of hypnotics or sedatives

          -  Alcohol abuse &gt;35 units per week

          -  Active treatment of ulcer within 3 months preoperatively

          -  Cancer disease

          -  Autoimmune disease incl. rheumatoid arthritis

          -  Pregnant or breast feeding women

          -  Menopause &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktoria Lindberg-Larsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Surgical Pathophysiology, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Bispebjerg</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Husted H. Fast-track hip and knee arthroplasty: clinical and organizational aspects. Acta Orthop Suppl. 2012 Oct;83(346):1-39. doi: 10.3109/17453674.2012.700593. Review.</citation>
    <PMID>23205862</PMID>
  </reference>
  <reference>
    <citation>Kehlet H. Fast-track hip and knee arthroplasty. Lancet. 2013 May 11;381(9878):1600-2. doi: 10.1016/S0140-6736(13)61003-X.</citation>
    <PMID>23663938</PMID>
  </reference>
  <reference>
    <citation>Grubb BP. Neurocardiogenic syncope and related disorders of orthostatic intolerance. Circulation. 2005 Jun 7;111(22):2997-3006. Review.</citation>
    <PMID>15939833</PMID>
  </reference>
  <reference>
    <citation>Bundgaard-Nielsen M, Jans Ø, Müller RG, Korshin A, Ruhnau B, Bie P, Secher NH, Kehlet H. Does goal-directed fluid therapy affect postoperative orthostatic intolerance?: A randomized trial. Anesthesiology. 2013 Oct;119(4):813-23. doi: 10.1097/ALN.0b013e31829ce4ea.</citation>
    <PMID>23756453</PMID>
  </reference>
  <reference>
    <citation>Bundgaard-Nielsen M, Jørgensen CC, Jørgensen TB, Ruhnau B, Secher NH, Kehlet H. Orthostatic intolerance and the cardiovascular response to early postoperative mobilization. Br J Anaesth. 2009 Jun;102(6):756-62. doi: 10.1093/bja/aep083. Epub 2009 Apr 27.</citation>
    <PMID>19398452</PMID>
  </reference>
  <results_reference>
    <citation>Jans Ø, Bundgaard-Nielsen M, Solgaard S, Johansson PI, Kehlet H. Orthostatic intolerance during early mobilization after fast-track hip arthroplasty. Br J Anaesth. 2012 Mar;108(3):436-43. doi: 10.1093/bja/aer403. Epub 2011 Dec 15.</citation>
    <PMID>22174345</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Viktoria Oline Lindberg-Larsen</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>Glucocorticoid</keyword>
  <keyword>Orthostatic Intolerance</keyword>
  <keyword>Heart Rate Variability</keyword>
  <keyword>Hip arthroplasty, total</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

